In vivo testing of cancer immunotherapies

Testing novel cancer immunotherapies in predictive mouse tumor models constitute a key step in the development of innovatives therapeutic approaches. In vivo studies in immune competent animals indeed enable to get a picture of the in vivo efficacy, as well as the underlying mechanism of action and safety profile of candidate immunotherapeutics.

Our In Vivo Syngeneic Tumor Models For Cancer Immunotherapy


To assess novel compounds aiming at enhancing anti-cancer immune response, Explicyte has developed tumor models using immunocompetent mice, and has characterized their response to chemotherapy, immunotherapy (TLR3 stimulation) and first-in-class immune checkpoint inhibitors (anti-CTLA-4 antibodies, anti-PD1/PDL1 axis modulators).

Preclinical Efficacy And Anti-Tumor Immune Response


  • Key readouts of in vivo efficacy: Experimental groups are monitored 3 times per week for tumor size, survival and body weight.
  • Reference cancer immunotherapies: Evaluate the efficacy of your test compound alone and/or in combination with validated gold standards immunotherapy.
  • Immune response profiling: Analyze key immunological markers at the tumor site and in peripheral compartments (blood, spleen, lymph nodes) using validated quantitative multiplex technologies such as flow cytometry and RT-qPCR.

in vivo studies cancer immunotherapy preclinical cro immune checkpoint inhibitors anti CTLA4 pd1 pdl1

Delays in tumor growth of CT26 (colorectal) upon CTLA-4 blockade, associated with a modulation of Treg/Th17 ratio. Mice were challenged with either CT26 tumor cells, and exposed to anti-CTLA-4 antibody. Tumor growth was followed by physical examination and immune profiling was performed on Tumor Draining Lymph Nodes samples by RT-qPCR for master genes of Treg / TH17 populations (FoxP3 and Rorc respectively).

Our added value


  • Collection of serological samples: Blood specimens can be collected from mouse over the entire study. This approach avoids to re-launch in vivo studies aiming at determining the peripheral immune response profile of responding or non-responding subgroups.
  • Bioluminescent imaging: For orthotopic tumor models (eg. intracranial glioblastoma), explicyte uses cell lines expressing 2nd generation luciferase (Luc2), allowing evaluation of tumor progression by in vivo live imaging.
  • Weekly reports: A weekly progress report enables our client to closely follow the efficacy profile of their compound and eventually adjust the experimental design (treatment protocol, blood sampling, etc.) with the support of our experts.

contact us

 I agree with the use of my personal data for further communications according to explicyte privacy policy

Explicyte immuno-oncology's preclinical contract research services include the vivo testing of cancer immmunotherapies. To conduct vivo studies, we have validated a range of syngeneic mouse tumour models treated with reference anti-cancer immunotherapies, such a anti CTLA-4 and anti-PD1/PD-L1 antibody therapies. To establish solid in vivo proof-of-concepts, we offer to determine the mechanism of action of compounds through the analysis of immune biomarkers at the tumor site and in peripheral compartments.